Company intelligence / Profile preview

Alfresa

Chiyoda-ku, Tokyo, Japanalfresa.com ↗
Ownership
Public · 2784
Employees
~12500
Development stage
Commercial
01

Overview

Alfresa is one of Japan’s largest healthcare groups specializing in the wholesale distribution of pharmaceuticals and medical devices. It also manufactures select proprietary drugs for neuropsychiatric and rare diseases. The group has commercialized several products including Modiodal for sleep disorders and Sabril for epilepsy. Its diagnostics division develops innovative tests such as fecal occult blood kits for cancer screening.

Therapeutic areas
GastroenterologyImmunologyNeurology
Modalities
Small moleculeDiagnostic reagentMedical device
Industry
Biotech
02

Drug pipeline

4 assets

gamma-aminobutyric acid

4

3 more assets in the full pipeline.

03

Partnerships

GEXVal Inc. for rare diseases drug developmentHitachi on regenerative medicine logistics platformsJapan Drone Organization for pharmaceutical delivery by drone
04

Financials

Market cap
$2.6B
Total revenue
$19.6B
Enterprise value
$1.5B

Beyond the preview

Go deeper on Alfresa.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

  • Partners
  • Deal terms
  • Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

  • Funding rounds
  • Investors
  • Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

  • Peer companies
  • Targets
  • Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

  • Platforms
  • Patents
  • Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

  • Company news
  • Sources
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alfresa.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call